

Special Issue

Tuberculosis Vaccines and Host-Directed Therapies

Message from the Guest Editor

Tuberculosis is a major cause of morbidity and disease. Despite the existence of the Bacille Calmette Guerin (BCG) vaccine and drug regimens, the global epidemic of tuberculosis continues to grow. It is important to develop new and effective vaccines to end the epidemic. While the BCG vaccine effectively prevents childhood pulmonary tuberculosis, its efficacy in adults varies. As a result, the World Health Organization and TB researchers are working to develop better alternatives to reduce the risk of tuberculosis. In this Special Issue, we will discuss the latest developments in TB vaccine research, including advanced studies on the mechanism of the BCG vaccine, challenges in developing better vaccines, and potential new vaccines and promising host-directed therapies.

Guest Editor

Dr. Shibali Das

Department of Medicine, Division of Cardiology, Washington University
in St. Louis, St. Louis, MO 63110, USA

Deadline for manuscript submissions

closed (30 November 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/196217

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).